208 related articles for article (PubMed ID: 38179049)
21. Effect of immunotherapy on the immune microenvironment in advanced recurrent cervical cancer.
Chen R; Yang W; Li Y; Cheng X; Nie Y; Liu D; Wang H
Int Immunopharmacol; 2022 May; 106():108630. PubMed ID: 35189471
[TBL] [Abstract][Full Text] [Related]
22. Case Report: Durable Complete Response After Combined Immunotherapy Following Resection of Primary Tumor in a Gallbladder Cancer Patient With Distant Metastatic Lymph Nodes of Favorable Immune-Microenvironment.
Yi B; Zhao Z; Dong H; Yuan L; Wu Y; Xu Y; Jiang X; Sun C; Wu D; Xiao Y
Front Immunol; 2022; 13():820566. PubMed ID: 35242133
[TBL] [Abstract][Full Text] [Related]
23. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Ma Z; Zhang W; Dong B; Xin Z; Ji Y; Su R; Shen K; Pan J; Wang Q; Xue W
Theranostics; 2022; 12(11):4965-4979. PubMed ID: 35836810
[No Abstract] [Full Text] [Related]
24. Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer.
Zhang H; Ye L; Yu X; Jin K; Wu W
Front Immunol; 2022; 13():956984. PubMed ID: 36225934
[TBL] [Abstract][Full Text] [Related]
25. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis.
Ho TTB; Nasti A; Seki A; Komura T; Inui H; Kozaka T; Kitamura Y; Shiba K; Yamashita T; Yamashita T; Mizukoshi E; Kawaguchi K; Wada T; Honda M; Kaneko S; Sakai Y
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33188035
[TBL] [Abstract][Full Text] [Related]
26. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer.
Datta J; Dai X; Bianchi A; De Castro Silva I; Mehra S; Garrido VT; Lamichhane P; Singh SP; Zhou Z; Dosch AR; Messaggio F; Ban Y; Umland O; Hosein PJ; Nagathihalli NS; Merchant NB
Gastroenterology; 2022 Dec; 163(6):1593-1612. PubMed ID: 35948109
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy.
Kawakubo K; Castillo CF; Liss AS
J Gastroenterol; 2022 Nov; 57(11):819-826. PubMed ID: 36048239
[TBL] [Abstract][Full Text] [Related]
28. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment.
Zhu YH; Zheng JH; Jia QY; Duan ZH; Yao HF; Yang J; Sun YW; Jiang SH; Liu DJ; Huo YM
Cell Oncol (Dordr); 2023 Feb; 46(1):17-48. PubMed ID: 36367669
[TBL] [Abstract][Full Text] [Related]
29. Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy.
Li R; Hao Y; Pan W; Wang W; Min Y
Acta Biomater; 2023 Nov; 171():482-494. PubMed ID: 37708924
[TBL] [Abstract][Full Text] [Related]
30. Multifunctional nanodrug performs sonodynamic therapy and inhibits TGF-β to boost immune response against colorectal cancer and liver metastasis.
Huang S; Ding D; Lan T; He G; Ren J; Liang R; Zhong H; Chen G; Lu X; Shuai X; Wei B
Acta Biomater; 2023 Jul; 164():538-552. PubMed ID: 37037269
[TBL] [Abstract][Full Text] [Related]
31. Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy.
Su L; Hao Y; Li R; Pan W; Ma X; Weng J; Min Y
Acta Biomater; 2022 Dec; 154():401-411. PubMed ID: 36241013
[TBL] [Abstract][Full Text] [Related]
32. Turning Up the Heat on the Pancreatic Tumor Microenvironment by Epigenetic Priming.
Nephew KP
Cancer Res; 2020 Nov; 80(21):4610-4611. PubMed ID: 33144295
[TBL] [Abstract][Full Text] [Related]
33. An Ionic Liquid Ablation Agent for Local Ablation and Immune Activation in Pancreatic Cancer.
Huang J; Wang M; Zhang F; Shao S; Yao Z; Zhao X; Hu Q; Liang T
Adv Sci (Weinh); 2023 Apr; 10(10):e2206756. PubMed ID: 36698308
[TBL] [Abstract][Full Text] [Related]
34. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
[TBL] [Abstract][Full Text] [Related]
35. Synergistic effects of radiotherapy and targeted immunotherapy in improving tumor treatment efficacy: a review.
Dar TB; Biteghe FAN; Kakar-Bhanot R; Aniogo EC; Malindi Z; Akinrinmade OA; Chalomie NET; Kombe Kombe AJ; Aboughe Angone S; Ndong JMN; Ndong JD
Clin Transl Oncol; 2022 Dec; 24(12):2255-2271. PubMed ID: 35913663
[TBL] [Abstract][Full Text] [Related]
36. Lighting Up the Fire in the Microenvironment of Cold Tumors: A Major Challenge to Improve Cancer Immunotherapy.
Benoit A; Vogin G; Duhem C; Berchem G; Janji B
Cells; 2023 Jul; 12(13):. PubMed ID: 37443821
[TBL] [Abstract][Full Text] [Related]
37. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
[TBL] [Abstract][Full Text] [Related]
38. Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert.
Li X; Gulati M; Larson AC; Solheim JC; Jain M; Kumar S; Batra SK
Semin Cancer Biol; 2022 Nov; 86(Pt 2):14-27. PubMed ID: 36041672
[TBL] [Abstract][Full Text] [Related]
39. Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy.
Smith C; Zheng W; Dong J; Wang Y; Lai J; Liu X; Yin F
World J Gastroenterol; 2022 Jul; 28(27):3297-3313. PubMed ID: 36158269
[TBL] [Abstract][Full Text] [Related]
40. The Role of Myeloid-Derived Suppressor Cells in the Treatment of Pancreatic Cancer.
Dong P; Yan Y; Fan Y; Wang H; Wu D; Yang L; Zhang J; Yin X; Lv Y; Zhang J; Hou Y; Liu F; Yu X
Technol Cancer Res Treat; 2022; 21():15330338221142472. PubMed ID: 36573015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
